Drug intelligence / Profile preview

beta-hydroxythiofentanyl

Development stage
Discontinued
Modality
Small Molecules
Administration
Oral, Intranasal, Intravenous, Inhalation
01

Overview

beta-Hydroxythiofentanyl is a synthetic opioid analgesic and a structural analog of fentanyl and thiofentanyl. It acts as an **agonist** at the µ-opioid receptor, producing effects similar to fentanyl, including potent analgesia, euphoria, and significant risk of respiratory depression. The compound has no accepted medical use in the United States or most other countries and is classified as a Schedule I controlled substance due to its high potential for abuse and lack of safety under medical supervision. It has been encountered on the illicit market since the mid 1980s, often sold as a powder or tablet—sometimes mixed with or misrepresented as heroin—and has been associated with fatal overdoses[1][3][5]. Like other fentanyl analogs, its side effects include itching, nausea, and life-threatening respiratory depression[3][5]. There are no approved therapeutic indications for this drug.

Other names
N-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-yl]-N-phenylpropionamideBetahydroxythiofentanyl
02

Targets

KOR (Kappa opioid receptor)MOR (Mu opioid receptor)DOR (Opioid Receptor Delta 1)

Beyond the preview

Go deeper on beta-hydroxythiofentanyl.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on beta-hydroxythiofentanyl.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call